KIM-1 Biomarker Analysis in the CAN-I Trial for Non-Clear Cell RCC - Wenxin Xu
Wenxin Xu
Wenxin (Vincent) Xu reviews KIM-1 biomarker data from the CAN-I trial, a phase 2 study of cabozantinib, ipilimumab, and nivolumab in non-clear cell renal cell carcinoma.
LITESPARK-024: Belzutifan Plus Palbociclib in Advanced Clear Cell RCC - David McDermott
David McDermott
David McDermott discusses LITESPARK-024, a study combining belzutifan with palbociclib in clear cell RCC based on preclinical evidence of synthetic lethality between VHL mutation and CDK4/6 inhibition.
